Understanding Lomustine: A Powerful Chemotherapy Drug 💊 #Lomustine is a chemotherapy drug used to treat serious conditions like brain tumors, melanoma, Hodgkin’s & non-Hodgkin’s lymphoma. As an alkylating agent, it damages cancer cell DNA, stopping their growth and division. Read More: https://wemarketresearch.com/reports/lomustine-market/1567 #CancerTreatment #Lomustine #Chemotherapy #Oncology #CancerAwareness #CancerResearch #BrainTumor #Melanoma #Lymphoma #HodgkinsLymphoma #NonHodgkinsLymphoma #CancerFighter #ChemoLife #CancerSupport #OncologyCare #MedicalScience #CancerWarrior #HealthAwareness

Antibody Drug Conjugate market Size, Share, Trends by 2035 The potential of antibody drug conjugates for the treatment of various disease indications, including cancer, is being slowly recognized in the pharmaceutical sector. Specifically, the success of these products can be attributed to their ability to effectively identify and eliminate diseased cells, along with low risk of side effects. The financial opportunity within the antibody drug conjugate market has been analyzed across the following segments:  Target Disease Indication  Acute Lymphoblastic Leukemia  Breast Cancer  B-Cell Lymphoma  Cervical Cancer  Gastric Cancer  Lung Cancer  Multiple Myeloma  Renal Cancer  Other Target Disease Indications  Therapeutic Area  Hematological Cancer  Solid Tumor  Linker  Hydrazone (4-(4-Acetylphenoxy) Butanoic Acid (Acbut)  Maleimide  Maleimidocaproyl  Succinimidyl-4-(N-Maleimidomethyl) Cyclohexane-1-Carboxylate  Tetrapeptide-Based Linker  Valine-Alanine  Valine-Citrulline  Other Linkers  Payload  DM1  DM4  Duocarmycin  Monomethyl auristatin E (MMAE)  Monomethyl auristatin F (MMAF)  Ozogamicin  SG3199  SN-38 / Irinotecan  Other Payloads  Target Antigen  BCMA (TNFRSF17 / BCM)  CD19  CD22  CD30  CD79b  CEACAM5  HER-2 (ERBB2)  Nectin 4  Tissue factor  TROP-2  Other Target Antigen  Key Geographical Regions  North America  Europe  Asia-Pacific and Rest of the World The Antibody Drug Conjugate Market (7th Edition), 2023-2035 report features the following companies, which we identified to be key players in this domain:  ADC Therapeutics  Astellas Pharma  AstraZeneca  Byondis  Daiichi Sankyo  Genentech  Gilead Sciences  ImmunoGen  Pfizer  RemeGen Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Market Landscape 5. Target Competitiveness Analysis 6. Company and Drug Profiles 7. Clinical Trial Analysis 8. Key Opinion Leaders 9. Combination Therapies 10. Partnerships and Collaborations 11. Funding and Investment Analysis 12. Patent Analysis 13. Academic Grants Analysis 14. Key Commercialization Strategies 15. Promotional Analysis 16. Success Protocol Analysis 17. Novel Conjugation and Linker Technology Platforms 18. Assessment of Non-Clinical Data First in Human Dosing 19. Cost Price Analysis 20. Case Study 1: Contract Manufacturing of Antibody-Drug Conjugates 21. Case Study 2: Companion Diagnostics for Antibody-Drug Conjugate Therapeutics 22. SWOT Analysis 23. Market Sizing and Opportunity Analysis 24. Executive Insights 25. Conclusion 26. Appendix 1: Tabulated Data 27. Appendix 2: List of Companies and Organizations To view more details on this report, click on the link: https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market/270.html Learn from experts: do you know about these emerging industry trends? Digital Therapies: The “Digital Pills” of current generation Medical Device Coatings and Modification Technologies Learn from our recently published whitepaper: - Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Learn more about Roots Analysis consulting services: Roots Analysis Consulting - the preferred research partner for global firms Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #ADCMarket #antibodydrugconjugate #antibodydrugconjugatemarket #MarketResearch #MarketInsights

Novel Antibody Therapies market Research Report by 2022, Forecast till 2035 Roots Analysis has done a detailed study on Novel Antibody Therapies Market covering key aspects of the industry’s evolution and identifying potential future growth opportunities. Key Market Insights  Presently, around 55 players across the globe are engaged in developing novel antibody therapies for the treatment of multiple disease indications; majority of large players are based in North America  Currently, majority of the radioimmunoconjugates are in clinical stages of development; more than 50% of the microbial immunotoxin candidates are administrated intravenously  Several big pharma players have undertaken a variety of initiatives for novel antibodies, ranging from proprietary product development to patent filing  550+ clinical trials related to novel antibody therapies have been registered till date; majority (44%) of these trials were / are being conducted across various clinical sites based in Europe  Over the past few years, more than 570 articles related to novel antibody therapies have been published by several eminent authors in high-impact journals; more than 50% of the articles were published in 2021  Since 2017, more than 4,600 patents have been granted / filed for various novel antibody therapies, demonstrating the rising interest and rapid pace of research in this field  The growing interest in this field is evident from the rise in partnership activity form the year 2020; a major proportion of the deals were signed by companies based in North America  With the rising demand for new therapeutic modalities with high efficacy, the novel antibody therapies market is likely to grow at a steady pace till 2035  The opportunity associated with novel antibody therapies market is likely to be well distributed across various types of therapies, route of administration and key geographical regions Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2 Market Segmentation 1.3. Research Methodology 1.4. Key Questions Answered 1.5. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Overview of Novel Antibody Therapies 3.2. Types of Novel Antibody Therapies 3.2.1. Antibody-Directed Enzyme Prodrug Therapy (ADEPT) 3.2.1.1. Mechanism of Action of ADEPT 3.2.1.2. Advantages of ADEPT 3.2.1.3. Disadvantages of ADEPT 3.2.2. TCR like Antibodies 3.2.2.1. Mechanism of Action of TCR like Antibodies 3.2.2.2. Advantages of TCR like Antibodies 3.2.2.3. Disadvantages of TCR like Antibodies 3.2.3. Radioisotope Immunoconjugates 3.2.3.1. Mechanism of Action of Radioisotope Immunoconjugates 3.2.3.2. Advantages of Radioisotope Immunoconjugates 3.2.3.3. Disadvantages of Radioisotope Immunoconjugates 3.2.4. Immunotoxins 3.2.4.1. Mechanism of Action of Immunotoxins 3.2.4.2. Advantages of Immunotoxins 3.2.4.3. Disadvantages of Immunotoxins 3.2.5. Intracellular Antibody 3.2.5.1. Mechanism of Action of Intracellular Antibody 3.2.5.2. Advantages of Intracellular Antibody 3.2.5.3. Disadvantages of Intracellular Antibody 3.2.6. Immunocytokines 3.2.6.1. Mechanism of Action of Immunocytokines 3.2.6.2. Advantages of Immunocytokines 3.2.6.3. Disadvantages of Immunocytokines 3.3. Therapeutic Antibodies: Development Approaches 3.4. Future Perspectives 4. NOVEL ANTIBODY THERAPIES: MARKET LANDSCAPE 4.1. Analysis Methodology and Key Parameters 4.2. Novel Antibody Therapies: Development Pipeline (Immunocytokines) 4.2.1. Analysis by Status of Development 4.2.2. Analysis by Mechanism of Action 4.2.3. Analysis by Type of Cytokine 4.2.4. Analysis by Status of Development and Type of Cytokine 4.2.5. Analysis by Type of Antigen / Format 4.2.6. Analysis by Dosing Frequency 4.2.7. Analysis by Type of Therapy 4.2.8. Analysis by Mode of Administration 4.2.9. Analysis by Route of Administration 4.2.10. Analysis by Target Disease Indication(s) 4.3. Novel Antibody Therapies: Development Pipeline (Immunotoxins) 4.3.1. Analysis by Status of Development 4.3.2. Analysis by Mechanism of Action 4.3.3. Analysis by Type of Toxin 4.3.4. Analysis by Dosing Frequency 4.3.5. Analysis by Type of Therapy 4.3.6. Analysis by Mode of Administration 4.3.7. Analysis by Immunotoxin Target 4.3.8. Analysis by Special Drug Designation 4.3.9. Analysis by Route of Administration 4.3.10. Analysis by Target Disease Indication(s) 4.4. Novel Antibody Therapies: Development Pipeline (Radioisotope Immunoconjugates) 4.4.1. Analysis by Status of Development 4.4.2. Analysis by Type of Radioisotopes 4.4.3. Analysis by Status of Development and Type of Radioisotopes 4.4.4. Analysis by Route of Administration 4.4.5. Analysis by Type of Therapy 4.4.6. Analysis by Dosing Frequency 4.4.7. Analysis by Mode of Administration 4.4.8. Analysis by Special Drug Designation 4.4.9. Analysis by Target Disease Indication(s) 4.5. Novel Antibody Therapies: Development Pipeline (Other Antibodies) 4.6. Novel Antibody Therapies: List of Developers 4.6.1. Analysis by Type of Player 4.6.2. Analysis by Company Size 4.6.3. Analysis by Year of Establishment 4.6.4. Analysis by Location of Headquarters (Region-wise) 4.6.5. Analysis by Location of Headquarters (Country-wise) 4.6.6. Analysis by Company Size and Region of Headquarters 4.6.7. Leading Players: Analysis by Number of Therapeutics 5. COMPANY PROFILES 5.1. Actinium Pharmaceuticals 5.1.1. Company Overview 5.1.2. Financial Information 5.1.3. Product Portfolio 5.1.4. Recent Developments and Future Outlook 5.2. Molecular Templates 5.2.1. Company Overview 5.2.2. Financial Information 5.2.3. Product Portfolio 5.2.4. Recent Developments and Future Outlook 5.3. Philogen 5.3.1. Company Overview 5.3.2. Financial Information 5.3.3. Product Portfolio 5.3.4. Recent Developments and Future Outlook 5.4. Roche 5.4.1. Company Overview 5.4.2. Financial Information 5.4.3. Product Portfolio 5.4.4. Recent Developments and Future Outlook 5.5. Seagen 5.5.1. Company Overview 5.5.2. Financial Information 5.5.3. Product Portfolio 5.5.4. Recent Developments and Future Outlook 5.6. Sesen bio 5.6.1. Company Overview 5.6.2. Financial Information 5.6.3. Product Portfolio 5.6.4. Recent Developments and Future Outlook 5.7. Telix Pharmaceuticals 5.7.1. Company Overview 5.7.2. Financial Information 5.7.3. Product Portfolio 5.7.4. Recent Developments and Future Outlook 5.8. Y-mAbs Therapeutics 5.8.1. Company Overview 5.8.2. Financial Information 5.8.3. Product Portfolio 5.8.4. Recent Developments and Future Outlook 6. CLINICAL TRIAL ANALYSIS 6.1. Analysis Methodology and Key Parameters 6.2. List of Clinical Trials Focused on Novel Antibody Therapies 6.2.1. Analysis by Trial Status 6.2.2. Analysis by Trial Registration Year 6.2.3. Analysis by Trial Registration Year and Trial Status 6.2.4. Analysis by Trial Phase 6.2.5. Analysis by Trial Phase and Patients Enrolled 6.2.6. Analysis by Trial Registration Year and Patients Enrolled 6.2.7. Analysis by Type of Sponsor / Collaborator 6.2.8. Analysis by Disease Indication(s) 6.2.9. Analysis by Study Design 6.2.10. Most Active Industry Players: Analysis by Number of Trials 6.2.11. Most Active Non-Industry Players: Analysis by Number of Trials 6.2.12. Analysis by Type of Treatment 6.2.13. Analysis by Type of Drug 6.2.14. Word Cloud Analysis: Emerging Focus Areas 6.2.15. Analysis by Top Indication(s) and Trial Phase 6.2.16. Analysis by Top Indication(s) and Leading Industry Players 6.2.17. Analysis by Trial Location 6.2.18. Analysis by Geography and Trial Status 7. PUBLICATION ANALYSIS 7.1. Analysis Methodology and Key Parameters 7.2. List of Publications Focused on Novel Antibody Therapies 7.2.1. Analysis by Year of Publication 7.2.2. Word Cloud Analysis: Emerging Focus Areas 7.2.3. Analysis by Type of Article 7.2.4. Top Authors: Analysis by Number of Publications 7.2.5. Key Journals: Analysis by Number of Publications 7.2.6. Key Journals: Analysis by Impact Factor 7.2.7. Most Popular Publishers: Analysis by Number of Publications 7.2.8. Most Popular Copyright Holders: Analysis by Number of Publications 8. PATENT ANALYSIS 8.1. Analysis Methodology and Key Parameters 8.2. List of Patents Focused on Novel Antibody Therapies 8.2.1. Analysis by Patent Publication Year 8.2.2. Year-wise Trend of Granted Patents 8.2.3. Analysis by Type of Patent 8.2.4. Analysis by Granted Patents and Patent Applications 8.2.5. Analysis by Geography 8.2.6. Analysis by CPC Symbols 8.2.7. Analysis by Type of Applicant 8.2.8. Analysis by Patent Age 8.2.9. Word Cloud Analysis: Emerging Focus Areas 8.2.10. Leading Industry Players: Analysis by Number of Patents 8.2.11. Leading Non-Industry Players: Analysis by Number of Patents 8.2.12. Leading Individual Assignees: Analysis by Number of Patents 8.2.13. Leading Players: Benchmarking by Patent Characteristics (CPC Symbols) 8.2.14. Patent Valuation: Analysis Methodology and Parameters 8.2.15. Patent Valuation: Analysis by Relative Valuation 9. PARTNERSHIPS AND COLLABORATIONS 9.1. List of Partnerships and Collaborations Focused on Novel Antibody Therapies 9.1.1. Analysis by Year of Partnership 9.1.2. Analysis by Type of Partnership 9.1.3. Analysis by Year and Type of Partnership 9.1.4. Most Popular Drug: Analysis by Number of Partnerships 9.1.5. Analysis by Types of Novel Antibodies 9.1.6. Analysis by Target Disease Indication(s) 9.1.7. Analysis by Type of Partnership and Target Indication(s) 9.1.8. Analysis by Type of Partner 9.1.9. Most Active Players: Analysis by Number of Partnerships 9.1.10. Most Active Players: Analysis by Type of Partnership 9.1.11. Regional Analysis of Partnerships 9.1.12. Intercontinental and Intracontinental Agreements 10. BIG PHARMA PLAYERS 10.1 Analysis Methodology and Key Parameters 10.2. Scoring Criteria for Key Parameters 10.3. List of Big Pharma Players Focused on Novel Antibody Therapies 10.3.1. Analysis by Supplier Strength 10.3.2. Analysis by Portfolio Strength 10.3.3. Analysis by Portfolio Diversity 10.3.4. Benchmarking: Spider Web Analysis 10.3.5. Benchmarking: Harvey Ball Analysis 10.3.6. Benchmarking: Wind Rose Chart 11. MARKET SIZING AND OPPORTUNITY ANALYSIS 11.1. Forecast Methodology and Key Assumptions 11.2. Global Novel Antibody Therapies Market, 2022-2035 11.3. Product-wise Sales Forecast (Marketed Drugs) 11.3.1. Adcetris (Seagen) 11.3.1.2. Sales Forecast 11.3.2. Elzonris (Menarini Group) 11.3.2.2. Sales Forecast 11.3.3. Pluvicto (Novartis) 11.3.3.2. Sales Forecast 11.4. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Type of Novel Antibodies 11.4.1 Novel Antibody Therapies Market for Immunocytokines, 2024-2035 11.4.2 Novel Antibody Therapies Market for Immunotoxin, 2023-2035 11.4.3 Novel Antibody Therapies Market for Radioisotope Immunoconjugates, 2023-2035 11.5. Global Novel Antibody Therapies Market, 2026 and 2035: Distribution by Target Disease Indication(s) 11.5.1 Novel Antibody Therapies Market for Acute Myeloid Leukemia, 2023-2035 11.5.2 Novel Antibody Therapies Market for Bladder Cancer, 2023-2035 11.5.3 Novel Antibody Therapies Market for Diffuse Large B-cell Lymphoma, 2025-2035 11.5.4 Novel Antibody Therapies Market for Graft-versus-host disease, 2026-2035 11.5.5 Novel Antibody Therapies Market for Melanoma, 2024-2035 11.5.6 Novel Antibody Therapies Market for Prostate Cancer, 2026-2035 11.5.7 Novel Antibody Therapies Market for Soft-tissue sarcoma, 2025-2035 11.6. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Type of Therapy 11.6.1. Novel Antibody Therapies Market for Combination Therapy, 2024-2035 11.6.2. Novel Antibody Therapies Market for Monotherapy, 2023-2035 11.7. Global Novel Antibody Therapies Market, 2023 and 2035: Distribution by Route of Administration 11.7.1. Novel Antibody Therapies Market for Intratumoral Drugs, 2023-2035 11.7.2. Novel Antibody Therapies Market for Intravenous Drugs, 2023-2035 11.7.3. Novel Antibody Therapies Market for Intravesical Drugs, 2023-2035 11.8. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Geography 11.8.1. Novel Antibody Therapies Market in North America, 2023-2035 11.8.2. Novel Antibody Therapies Market in Europe, 2025-2035 11.8.3. Novel Antibody Therapies Market in Asia Pacific, 2023-2035 11.9. Product-wise Sales Forecast (Phase III Drugs) 11.9.1. Adcetris (Seagen) 11.9.1.1. Target Patient Population 11.9.1.2. Sales Forecast 11.9.1.3. Net Present Value 11.9.1.4. Value Creation Analysis 11.9.2. Fibromun (Philogen) 11.9.2.1. Target Patient Population 11.9.2.2. Sales Forecast 11.9.2.3. Net Present Value 11.9.2.4. Value Creation Analysis 11.9.3. Iomab-B (Actinium Pharmaceuticals) 11.9.3.1. Target Patient Population 11.9.3.2. Sales Forecast 11.9.3.3. Net Present Value 11.9.3.4. Value Creation Analysis 11.9.4. Nidlegy (Philogen) 11.9.4.1. Target Patient Population 11.9.4.2. Sales Forecast 11.9.4.3. Net Present Value 11.9.4.4. Value Creation Analysis 11.9.5. T-Guard (Xenikos) 11.9.5.1. Target Patient Population 11.9.5.2. Sales Forecast 11.9.5.3. Net Present Value 11.9.5.4. Value Creation Analysis 11.9.6. TLX 591 (Telix Pharmaceuticals) 11.9.6.1. Target Patient Population 11.9.6.2. Sales Forecast 11.9.6.3. Net Present Value 11.9.6.4. Value Creation Analysis 11.9.7. Vicinium (Sesen Bio) 11.9.7.1. Target Patient Population 11.9.7.2. Sales Forecast 11.9.7.3. Net Present Value 11.9.7.4. Value Creation Analysis 12. APPENDIX 1: TABULATED DATA 13. APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS To view more details on this report, click on the link: https://www.rootsanalysis.com/reports/novel-antibody-therapies-market.html You may also be interested in the following titles: Cell Therapy Manufacturing Market Global TCR Therapy Market You may also like to learn what our experts are sharing in Roots educational series: Is Blue Ocean Strategy The Silver Bullet For Emerging Teleradiology Players to Achieve A Breakthrough In This Highly Competitive Market? CAR-T Cell Therapies: Addressing Key Unmet Needs Across Various Oncological Indications About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #NovelAntibodyTherapiesMarket #NovelAntibodyTherapiesMarketGrowth #NovelAntibodyTherapies #intrabodies #novelantibodies

GENOTOXICITY / MUTAGENICITY TESTING Genotoxicity refers to the property of physical, chemical, and biological agents to cause damage to genetic information present within a cell. It is worth mentioning that this damage can lead to formation of mutations, activation of mistimed event and direct DNA damage. Further, researchers have been able to link the mutations caused by genetic toxicology to various disease indications, including several oncological and genetic disorders. In addition, it is believed that the changes introduced in the genetic material can be passed down to future cell generations. Similarly, mutagenicity refers to the introduction of perpetual transmissible changes in the genomic structure of organisms, enabling mutations in cells. Therefore, testing of genotoxicity / mutagenicity is an essential component of the safety assessment of products, with the objective of preventing certain particles from negatively impacting the human health. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/genotoxicity-testing-services-market/request-sample.html Testing techniques used for genotoxicity / mutagenicity testing:  Ames test: It is used to evaluate an agent’s mutagenic potential by reversing mutations in the tester mutant bacteria (E. coli, Salmonella typhi), as well as its ability to synthesize an essential amino acid required for growth.  Mouse Lymphoma Assay / Hypoxanthine Guanine Phosphoribosyl Transferase: Mouse Lymphoma Assay is employed to assess an agent’s genotoxic potential. It determines the genetic variations affecting the expression of the thymidine kinase gene located on chromosome.  Mutation Assay: Transgenic rodent somatic and germ cell gene mutation assay specifies an in vivo assay that perceives gene mutation causing agents. Transgenic mice or rats with several copies of chromosomally integrated plasmids or phage shuttle vectors are employed in this test.  Comet Assay: The comet assay, also known as single cell gel electrophoresis (SCGE), is an efficient technique for identifying DNA strand breaks in a cell. It is used in molecular epidemiology, genotoxicity testing, and basic studies on DNA damage and repair.  Chromosomal Aberration Test: The test is used to evaluate a substance's possible genotoxic risk. Mammalian cells are cultivated in vitro, exposed to a test substance, extracted, and then the frequency of structural asymmetry of the chromosomes is determined.  Micronucleus Test: The micronucleus identifies chemicals (liquid or solid) that lead to cytogenetic damage, resulting in the formation of micronuclei containing complete or lagging chromosomal segments. Hence, it can be concluded that players offering services for genotoxicity / mutagenicity testing have now become an integral part of various industries. Furthermore, considering the various active initiatives being undertaken by players based in this domain, we are led to believe that the opportunity for stakeholders in this industry is likely to grow at an exponential pace in the foreseen future. For additional details, please visit https://www.rootsanalysis.com/reports/genotoxicity-testing-services-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. 4D Bioprinting Market : Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com